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Background: Cough is a common presenting symptom in patients with idiopathic interstitial pneumonia
(IIP); it is often disabling, and lacks effective treatment. Studies in animals suggest that carcainium
chloride, a quaternary derivative of the local anesthetic lidocaine, is able to inhibit experimentally
induced cough by a mechanism of action distinct from that of lidocaine.
Objective: To determine the effectiveness of aerosolised carcainium chloride (VRP700) in controlling
cough in patients with IIP.
Methods: Eight female patients (mean age 71 years) with IIP were investigated in a double blind,
randomised, placebo controlled crossover, adaptive contingency study design (EudraCT Number 2010-
021350-19). The study consisted of a screening visit to assess the eligibility of patients, and two separated
(48e72 h) study days. On the two study days, patients were randomised to receive either nebulized
VRP700 (1.0 mg/kg) on the first study visit followed by nebulised placebo (sodium chloride 0.9%) on the
second visit, or placebo on the first visit followed by VRP700 on the second visit. The primary endpoint
was cough frequency over a 4-h assessment period; secondary endpoints were subjective cough-related
level of discomfort as assessed by a visual analogue scale (VAS) and the subjective response to treatment
as assessed by a quality of life question. Safety (ECG, spirometry, urine and blood tests) and adverse
events occurring during the trial were also investigated.
Results: In all patients both VRP700 and placebo decreased cough frequency; however, mean decreases
in cough frequency after treatment with VRP700 were significantly (P < 0.001) higher than with placebo.
Similarly, mean reductions in VAS score were significantly (P < 0.001) higher after treatment with VRP
700 compared with placebo. All but one patient indicated that they felt better after receiving VRP700. No
adverse events were reported during the study, nor were any changes in ECG variables, spirometry, urine
and blood tests noted.
Conclusion: The results of this exploratory study indicate that nebulised VRP700 improved cough and
quality of life in hospitalised IIP patients with no significant side effects. A larger trial is warranted to
assess these promising results.
© 2016 Elsevier Ltd. All rights reserved.thic interstitial pneumonia;
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ini).1. Introduction
Chronic cough remains a serious unmet medical need [1,2].
Cough is a nerve reflex involving the activation of vagally inner-
vated receptors ultimately resulting in cough motor events [3].
Receptors (sensors) implicated in the cough reflex have been found
on families of both thin myelinated (Ad) and unmyelinated bron-
chial and pulmonary C sensory nerve fibres [4,5] Not surprisingly,
therefore, local anaesthetics can inhibit coughing presumably via
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are known to interfere with other important protective reflexes
such as the gag reflex [7], limiting their wider use in the clinic.
Carcainium chloride, that is structurally related to the local
anaesthetic lidocaine [8], has been reported to reduce cough re-
sponses in guinea pigs and rabbits by selective inhibition of Ad fi-
bres when applied topically to the airways, whilst having no
inhibitory effect on bronchial or pulmonary C-fibres, which were
both inhibited by topical lidocaine [9]. To our knowledge, this
selectivity for Ad fibres has not been reported so far for other drug
classes. However, to date no studies investigating the effect of
inhaled carcainium chloride on cough responses have been re-
ported in humans.
This pilot study, therefore, aimed to investigate the effectiveness
of inhaled carcainium chloride (hereafter named VRP700) in con-
trolling cough of patients with idiopathic interstitial pneumonia
(IIP) [10]. Patients with IIPs were chosen since cough is a distressing
and disabling symptom of this disease [10].
2. Methods
2.1. Study design and participants
This was a randomised, double blind, crossover, placebo
controlled study performed according to an adaptive contingency
design [11].We enrolled adult, non-smoking inpatients with IIP and
refractory chronic cough [12]. We excluded patients who reported
<1 month respiratory tract infections, who were taking an
angiotensin-converting enzyme inhibitor, or who had liver or renal
dysfunction. Women breastfeeding or of childbearing agewere also
excluded. Written consent was obtained from each patient; the
study was approved by the Ethics Committee of the Careggi Hos-
pital (EudraCT number 2010-021350-19).
2.2. Protocol and recording procedures
After screening, each patient was examined on two separate
(48e72 h) occasions (Fig. 1). On each occasion, patients randomly
inhaled 1.0 mg/kg VRP700 or placebo (sodium chloride 0.9%) by
means of a DeVilbissUltraNeb 3000 nebuliser set to produce 2 mL/
min of aerosol. Administration continued until nebulisation
occurred; a ~1.2 mL residue remained in the nebuliser cup after
each nebulisation. After study completion, patients were followed
up for a further 12e24 h. On all occasions, the cough frequency was
recorded at baseline and for 4 h after the completion of each
inhalation period bymeans of a cough recorder (PulmoTrack® 2010
W-Holter, Karmelsonic) [13] and expressed as coughs per hourFig. 1. Study flow chart. PK, pharm(cph). Cough-related level of discomfort was investigated by a 10-
cm visual analogue scale (VAS), with the extremes indicating no
discomfort (0 cm) or extreme discomfort (10 cm). Patients' sub-
jective response to treatments was also assessed 4 h post treat-
ment asking the patients: “how do you feel: worse, same or better
following treatment?” Similarly, physicians' judgement (i.e. supe-
rior, same, inferior) of individual patient responses in terms of
anti-tussive actions compared to baseline was also obtained. Vital
signs, ECG and spirometry variables were recorded at baseline and
15, 20, 40, 60, 90, 120 min, 3 and 4 h after drugs administration.
Concomitant medication changes and adverse events were re-
ported. Blood and urine samples were collected for standard safety
laboratory assessments; blood samples were also taken at base-
line, at 20, 40, 60, 90, 120 min and 3, 4 h after VRP700 inhalation to
calculate the maximum plasma concentration (Cmax) and time to
reach Cmax (Tmax) [14].
2.3. Data analysis
The primary outcome variable was cough frequency over a 4-h
assessment period measured before and after VRP700 and pla-
cebo administration; secondary outcome variables were VAS
scores, patients' subjective response and physicians' judgement.
Categorical data were expressed as percentages, whereas normal
distributed data were presented as mean ± SD. For efficacy pa-
rameters, all tests for a difference between the two treatments have
been two-sided and performed at the 5% significance level.
3. Results
Eight female patients (Table 1) completed the study with no
significant changes in vital signs, ECG variables, spirometry, as well
as in any parameters measured in blood or urine. Preliminary CT
scans indicated that six patients suffered from usual interstitial
pneumonia, one had non-specific interstitial lung disease, and
another one had an unclassifiable IIP. No patients reported adverse
events during the study. However, they consistently coughed more
during the 1st or 2nd minutes of nebulisation of active drug, fol-
lowed by a marked decrease in cough over the rest of nebulisation
period. As the cough monitor was not started until after inhalation
had completed, these initial coughs have not been recorded.
In the patients as a group, Cmax for VRP700 ranged from 2.26 to
37.7 ng/mL with a Tmax of 20 min.
VRP700 significantly decreased cough frequency from
57.75 ± 15.51 cph to 13.13 ± 9.62 cph 4 h after VRP700 adminis-
tration (p < 0.001, Fig. 2). With placebo, the same variable
decreased from 46.06 ± 10.70 cph to 37.38 ± 19.34 cph (NS).acokinetic; See text for details.
Table 1
Patients ‘characteristics.
Pt. no. Sex Age (years) BMI FEV1 (% pred.) FVC (% pred.) TLC (% pred.) DLCO (% pred.) Main ongoing treatment
1 F 75 27.07 63 60 62 49 OCS, PPI, N-ACC
2 F 79 27.00 NA NA NA NA OCS, PPI, N-ACC
3 F 75 30.05 88 90 80 65 PPI, N-ACC
4 F 75 28.00 70 64 65 59 OCS, PPI
5 F 56 23.15 88 91 99 70 OCS
6 F 69 36.10 81 76 61 32 OCS, PPI,Ox
7 F 68 33.01 80 82 77 60 OCS, PPI,Ox, N-ACC
8 F 71 29.00 66 66 64 48
Mean e 71.00 28.00 76.57 75.57 72.57 54.71
SD 7.07 1.00 10.26 12.62 13.84 12.78
BMI, body mass index; DLCO, diffusing lung capacity; FEV1, forced expiratory volume at 1 s; FVC, forced vital capacity; NA, not available; N-ACC, N-Acetylcysteine; OCS, oral
corticosteroids; Ox, oxygen; Pt, patient; PPI, proton pump inhibitors; pred, predicted value; TLC, total lung capacity.
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and placebo demonstrated a much higher reduction (P < 0.001) in
cough frequency with the active drug rather than with placebo
(Fig. 1).
In all patients, VRP700 reduced (P < 0.001) baseline VAS scores
with an overall mean reduction of 5.60 ± 0.90. For the placebo
treatment, in four patients the post-placebo values were lower than
the pre-placebo values with an overall mean reduction of 1.8 ± 1.0Fig. 2. Individual values of cough frequency (upper panel) and visual analogue scale
(VAS) score (lower panel) recorded pre and post drug or placebo administration. Bars
represent median values.(Fig. 2). As with cough frequency, comparisons of mean changes in
VAS score with VRP 700 and placebo demonstrated a significantly
(P < 0.001) higher reduction in VAS score with the active drug
rather than with placebo (Fig. 2). Scrutiny of data (Fig. 2) indicated
that in 4 patients treated with the sequence VRP700-placebo, the
cough frequency values and VAS scores were smaller after placebo
than after the reverse sequence.
All patients indicated that they felt better after receiving
VRP700. Only 1 patient felt better after receiving placebo and one
felt worse: the remaining patient reported no appreciable change;
so that the difference between the 2 treatments was statistically
significant (P < 0.02 by Chi squared). In all patients, physicians
selected VRP700 as being the more effective (P < 0.01) treatment in
reducing the patient's cough frequency.4. Discussion
We have demonstrated a marked antitussive effect of nebulised
VRP700 in patients with chronic cough and IIP with an overall 80%
reduction in cough frequency. Patients also reported a remarkable
subjective improvement, also confirmed by medical evaluation.
VRP700 appears to be safe since none of the patients reported any
clinically relevant side effect, notably no paraesthesia that has been
reported following treatment with local anaesthetics.
One limitation of the crossover study design is the so-called
carry over effect [15]. Indeed, four patients showed a larger
reduction in cough frequency and VAS score when they received
the sequence VRP700-placebo rather than the sequence placebo-
VRP700, thus suggesting that prior exposure to the active drug
may have enhanced the subsequent responses to placebo. However,
overall, the active drug proved to be far more effective than placebo
in the patients as a group, although there were insufficient samples
to test for statistical significance of the sequence effect in the study
population. On the other hand, the advantage of the statistical
method used here [11] is that it does not require an initial
commitment to a large sample size, since the ultimate sample size
was determined by the data generated during the study.
The reason for female patients being studied reflected that pa-
tient recruitment was consecutive, and the greater severity of the
disease in females [16] may have contributed.
The exact mechanism(s) underlying cough in IIP remains un-
clear [17]. For instance, more than 50% of patients with interstitial
lung disease could have cough caused by other causes such as
asthma, rhinitis or gastro-oesophageal reflux [18,19]. However, IIP
may directly cause cough as inflammation is not limited to the
parenchyma, and disrupted airway epithelium [20] with inflam-
matory mediators known to provoke cough having been detected
in such patients [17,18]. A further possible cause of cough in
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fibrosis, which results in traction bronchiectasis [21].
Whilst the molecular mechanism of action of VRP700 remains
incompletely understood, this is highly unlikely to be due to any
local anaesthetic activity of this drug as it has a distinct electro-
physiological profile from lidocaine on airway sensory nerves [9]. In
addition, VRP700 inhibits the activation of airway Ad fibres selec-
tively [9], a finding in keeping with a major role for Ad fibres in
many patients with chronic cough.
The antitussive effect of VRP700 is comparable to that recently
reported using a P2X3 purinergic receptor antagonist (AF-219) in
patients with refractory chronic cough [22]. However, unlike AF-
219, which was associated with loss of taste in the majority of pa-
tients, VRP700 was not associated with any major side effects.
In conclusion, VRP700 may be promising and safe in patients
with IIP. Whether the drug is also suitable for long-term adminis-
tration and in the management of patients with intractable cough
of different origin remains to be ascertained.
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